SEPN
Septerna IncHealthcare · $1.8B market cap
Verdict
We can't put a fair value on SEPN right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow SEPN
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases, 1 sale worth $126K and 2 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Other filings
About Septerna Inc
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works